Redx Pharma: Cashed up to take its assets to 'value inflexion' points
Last updated: 06:54 28 Feb 2024 EST, First published: 01:13 08 Feb 2021 EST
Snapshot
- Redx Pharma launches trial of 'first-in-class' Crohn's disease drug
- Redx Pharma strikes balance between in-house programmes and partnerships
- Redx Pharma achieves milestone with dosing of first participant in Phase 1 clinical trial for RXC008
About the company
Redx Pharma PLC is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, targeted medicines for the treatment of fibrotic disease, cancer and the emerging area of cancer-associated fibrosis.
How it is doing
Redx Pharma PLC (AIM:REDX) said it has kicked off a phase I clinical trial for RXC008, a 'first-in-class' ROCK inhibitor treatment targeting fibrostenotic Crohn's disease.
This study aims to assess the safety and pharmacokinetic profile of the drug - in other words, its activity in the body over some time, including the processes by which RXC008 is absorbed, distributed in the body, localised in the tissues, and excreted.
It will be assessed in healthy volunteers with the results from the study expected by the end of this year.
Chief executive Lisa Anson told investors: "We are delighted to confirm that the first participant has been dosed in the RXC008 phase I clinical study.
Redx Pharma PLC (AIM:REDX) has played down a report it planning a New York listing.
"Redx wishes to clarify that it is not currently in any process relating to a listing in the US, nor any other jurisdiction," the company said in a brief stock exchange missive.
Shares in Redx Pharma PLC (AIM:REDX) jumped 14% in opening trade after it inked a deal with Jazz Pharma worth a headline US$880 million.
It is the second transaction with Jazz and its fourth in total, with AstraZeneca and a subsidiary of Eli Lilly among making up the other names on the collaboration roster.
Insight: Redx Pharma strikes balance between in-house programmes and partnerships
Redx Pharma PLC (LON:REDX) is comfortable after having found a balance between in-house programmes and partnerships with other companies.
This week the biotech announced a collaboration, the first of this kind since its creation in 2010, with US company Jazz Pharmaceuticals to discover and develop two targeted cancer therapies.
What management says
Redx Pharma PLC (AIM:REDX) CEO Lisa Anson discusses the enrollment of the first participant in its RXC008 Phase 1 clinical trial in an interview with Proactive's Stephen Gunnion.
RXC008 is a 'first-in-class' ROCK inhibitor, designed to be gut-restricted, targeting fibrostenotic Crohn's disease. This oral molecule inhibits ROCK1 and ROCK2, aiming to avoid systemic side effects like hypertension, and providing targeted action in the gut. This development marks a significant step from laboratory to patient-focused clinical development.